Table 1. Characteristics of Study Population.
| A-NHL Cases (n = 47) | Controls (n = 48) | |
| Age (years), range (median) | 25–56 (42) | 26–56 (40) |
| Race, n (%) | ||
| White | 46 (98) | 47 (98) |
| Black | 1 (2) | 1 (2) |
| CD4+ T Cell Count (cells/mm3), range (mean) | 7–788 (146) | 6–794 (193) |
| Receiving HAART [31], n (%) | ||
| Current | 6 (13) | 5 (10) |
| Former | 1 (2) | 1 (2) |
| Never | 38 (81) | 42 (87.5) |
| Unknown | 2 (4) | 0 (0) |
| HBV Serology, n (%) | ||
| Positive | 41 (87) | 42 (87.5) |
| Negative | 3 (6) | 6 (12.5) |
| Unknown | 3 (6) | 0 (0) |
| HHV-8 Serology, n (%) | ||
| Positive | 28 (57) | 35 (73) |
| Negative | 9 (19) | 9 (19) |
| Unknown/Indiscriminate | 10 (21) | 4 (8) |
| NHL Subtype, n (%) | ||
| B-cell Diffuse | 20 (43) | |
| CNS | 11 (23) | |
| BL, BL-like | 7 (15) | |
| NHL, NOS | 6 (13) | |
| Other | 3 (6) |
HAART – highly active antiretroviral therapy; HBV/HHV-8 status obtained at time of blood draw; CNS – central nervous system; BL – Burkitt's lymphoma; NOS – not otherwise specified.